Unicycive Therapeutics (UNCY) Cash from Financing Activities (2020 - 2026)
Unicycive Therapeutics posted quarterly Cash from Financing Activities of $19.6 million for Q1 2026, up 668.62% year-on-year from $2.5 million in Q1 2025, and up 196.23% on a QoQ basis from $6.6 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 6 years of Cash from Financing Activities data on file, last reported at $19.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 668.62% year-over-year to $19.6 million; the trailing twelve-month figure through Mar 2026 stood at $63.5 million (up 3167.68% YoY), and the FY2025 full-year result was $46.5 million, up 3.06% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $19.6 million, up from $6.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $45.7 million in Q1 2024 and bottomed at -$811000.0 in Q2 2024.
- The 4-year median for Cash from Financing Activities is $4.6 million (2025), against an average of $11.6 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities slumped 207.84%; it then soared 16871.97% in 2025.
- A 4-year view of Cash from Financing Activities shows it stood at -$205000.0 in 2023, then surged by 278.05% to $365000.0 in 2024, then surged by 1709.86% to $6.6 million in 2025, then soared by 196.23% to $19.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $19.6 million (Q1 2026), $6.6 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 19.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.57 Mn |
| Mar 31, 2026 | 19.57 Mn |
| Dec 31, 2025 | 6.61 Mn |
| Dec 31, 2025 | 6.61 Mn |
| Sep 30, 2025 | 26.33 Mn |
| Sep 30, 2025 | 26.33 Mn |
| Jun 30, 2025 | 10.98 Mn |
| Jun 30, 2025 | 10.98 Mn |
| Mar 31, 2025 | 2.55 Mn |
| Mar 31, 2025 | 2.55 Mn |
| Dec 31, 2024 | 365,000.00 |
| Dec 31, 2024 | 365,000.00 |
| Sep 30, 2024 | -157,000.00 |
| Sep 30, 2024 | -157,000.00 |
| Jun 30, 2024 | -811,000.00 |
| Jun 30, 2024 | -811,000.00 |
| Mar 31, 2024 | 45.69 Mn |
| Mar 31, 2024 | 45.69 Mn |
| Dec 31, 2023 | -205,000.00 |
| Dec 31, 2023 | -205,000.00 |
| Sep 30, 2023 | -51,000.00 |
| Sep 30, 2023 | -51,000.00 |
| Mar 31, 2023 | 27.80 Mn |
| Mar 31, 2023 | 27.80 Mn |
| Sep 30, 2021 | 21.48 Mn |
| Sep 30, 2021 | 21.48 Mn |
| Jun 30, 2021 | 71,000.00 |
| Jun 30, 2021 | 71,000.00 |
| Mar 31, 2021 | 820,000.00 |
| Mar 31, 2021 | 820,000.00 |
| Dec 31, 2020 | 475,000.00 |
| Dec 31, 2020 | 475,000.00 |
| Sep 30, 2020 | 768,000.00 |
| Sep 30, 2020 | 768,000.00 |